MCOLN1 and Parkinson disease: TRPML1 has also been implicated in various neurological diseases, and because of the positive impact of TRPML1 on lysosomal biogenesis and autophagy (Scotto Rosato et al., 2019; Santoni et al., 2020), TRPML1 agonists have been considered for the treatment of PD (Poewe et al., 2017; Santoni et al., 2020).